JFG
MLTX icon

Jefferies Financial Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Jefferies Financial Group’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,500
Closed -$755K – 1865
2023
Q4 		$755K Buy
+12,500
New +$644K ﹤0.01% 1073

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jefferies Financial Group's MLTX Position: Q1 2026 in Review

Jefferies Financial Group held its MoonLake Immunotherapeutics (MLTX) position steady in Q1 2026 at 500,000 shares worth $9.32M. The position accounts for 0.06% of the portfolio, ranked #214.

Jefferies Financial Group first reported a position in MLTX in Q4 2022 and has held it in 11 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Jefferies Financial Group held 500,000 shares of MoonLake Immunotherapeutics worth $9.32M as of Q1 2026.
  • Jefferies Financial Group left its MoonLake Immunotherapeutics share count unchanged in Q1 2026.
  • MoonLake Immunotherapeutics made up 0.06% of Jefferies Financial Group's portfolio in Q1 2026, its #214 holding.
  • Jefferies Financial Group first reported a position in MoonLake Immunotherapeutics in Q4 2022 and has held it in 11 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.